BAM
TVTX icon

Blueshift Asset Management’s Travere Therapeutics TVTX Stock Holding History

Blueshift Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-9,389
Closed -$227K – 846
2022
Q2 		$227K Sell
9,389
-12,190
-56% -$307K 0.04% 543
2022
Q1 		$556K Buy
+21,579
New +$573K 0.05% 405

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Blueshift Asset Management's TVTX Position: Q3 2022 in Review

Blueshift Asset Management sold out of Travere Therapeutics (TVTX) in Q3 2022, closing a stake of 9,389 shares — an estimated $227K sold.

Blueshift Asset Management first reported a position in TVTX in Q1 2022 and held it in 2 quarters. The position peaked at $556K in Q1 2022. 171 funds tracked by Wall St. Rank hold TVTX as of Q3 2022.

  • Blueshift Asset Management reported no remaining Travere Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Blueshift Asset Management sold 9,389 Travere Therapeutics shares in Q3 2022, an estimated $227K.
  • Blueshift Asset Management first reported a position in Travere Therapeutics in Q1 2022 and held it in 2 quarters.
  • Blueshift Asset Management's Travere Therapeutics position peaked at $556K in Q1 2022.
  • 171 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2022.

Based on Blueshift Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.